Clinical Trial

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-30; most recent amendment 2025-09-15.
Trial Details
NCT Number NCT07010692
Lead Sponsor Bruce Robinson, MD
Conditions Keratinocyte Carcinoma, Basal Cell Carcinomas, Squamous Cell Carcinoma, Skin Cancer
Enrollment 100 participants
Start Date 2025-05-16
Primary Completion 2030-05 (estimated)
Study Completion 2030-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-17